Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ICONIC LABS PLC AGM Information 2020

Feb 27, 2020

4953_rns_2020-02-27_7df14998-e640-44dc-be9b-73475c0eb9b2.pdf

AGM Information

Open in viewer

Opens in your device viewer

Iconic Labs PLC 27 February 2020

Iconic Labs Plc ("Iconic Labs" or the "Company") Results of General Meeting

Iconic Labs plc (AIM: ICON), a multi-divisional new media and technology business, advises that it held a General Meeting (" GM") earlier today.

All resolutions were duly passed on a poll vote. Details of the proxy voting are shown in the table below.

Resolutions Votes For % Votes
Against
% Votes Total Votes
Withheld
1 Authority to
sub-divide shares
and adopt new
articles
153,111,913 88.11 20,665,281 11.89 173,777,194 1,500,000
(Special
Resolution)
2 Authority to
issue notes and
warrants under
Deed of Issuance
and Financing
and Settlement
Agreement
153,111,913 88.11 20,665,281 11.89 173,777,194 1,500,000
(Ordinary
Resolution)
3. Empowering
the directors' to
disapply statutory
pre-emption
rights
152,498,075 87.75 21,279,119 12.25 173,777,194 1,500,000
(Special
Resolution)

The Company also acknowledges the continual concerns raised by shareholders as to the underlying identity of the holders of its shares and the need for the Company to publish an accurate updated shareholder register. To that end, the Company issued notices to several shareholders pursuant to its articles requiring disclosure of underlying beneficial holders. In accordance with the articles, such shares are disenfranchised until the shareholder complies with the notice.

Iconic Labs PLC

For information please contact:

Damon Heath Shard Capital Partners LLP Tel: +44 (0) 20 7186 9950

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contac[email protected] or visit www.rns.com.

END

ROMUBSURRBUUUAR